A new research study, published by Report Ocean, observes that the global ornithine-transcarbamylase deficiency market is demonstrating a high growth rate. The report, titled “Global Ornithine-Transcarbamylase Deficiency Market Size study, by Type (DTX-301, SEL-313, SHP-641, PRX-OTC and Others), By Application (Hospital, Clinic and Others) and Regional Forecasts 2020-2027,” offers a detailed insight into this market, with analysts performing a thorough market assessment, considering its past performance and future prospects.
According to the research report, the increasing incidence rate of urea cycle disorders (UCDs) in humans is driving the demand for efficient ornithine-transcarbamylase (OTC) deficiency treatment across the world. Riding on the back of this trend, the global OTC deficiency market is registering a tremendous rise. UCDs are among some of the genetically inherited diseases, which impact the human body’s waste removal systems. Patients, suffering from UCDs, cannot produce enough catalytic enzymes that are required to convert excessive nitrogen produced in human body into urea. This results in excessive ammonia deposition and increase toxicity in the human body. To cater to need of patients optimally, various pharmaceutical firms are conducting research to identify possible novel approaches to develop an effective treatment for this disorder. The increasing investments in research activities and development of new treatments and medications are likely to aid the expansion of the worldwide ornithine transcarbamylase deficiency treatment market size, states the research report.
North America Leads Global Ornithine-Transcarbamylase Deficiency Market
Among regional markets for OTC deficiency, North America held the leading position in 2019. The high number of reported cases, ongoing clinical studies for urea cycle disorders, favorable reimbursement policies, and better screening methods for rare disorders assisted the regional market to gain such prominence.
Across the US, the prevalence OTC deficiency ranges from one in fourteen thousand to one in seventeen thousand individuals, states the U.S National Library of Medicine. With such a high range of prevalence, the demand for treatment is also significantly high, attracting prominent market players to increase their investments across North America, which is projected to add to the growth of North America OTC deficiency market in the years to come.
The Asia Pacific OTC deficiency market is projected to expand at a relatively high CAGR over the forecast period, thanks to the increasing awareness among people about OTC deficiency and other urea cycle disorders. The surge in screening, rise in distribution partnerships between key players, and the increase in investments for R&D in this region is also expected to support this market over the near future.
Impact of Covid 19 on Global Ornithine-Transcarbamylase Deficiency Market
The Covid 19 pandemic has severely impacted the patients, who are already suffering from other medical conditions, such as diabetes, hypertension, cardiovascular issues, or renal problems. OTC deficient patients are also among the highly vulnerable pool. Healthcare providers and pharmaceutical companies are working together to increase the supply of necessary drugs, creating lucrative opportunities for drugmakers. Companies functional in the ornithine transcarbamylase deficiency treatment market are cashing on these opportunities by increasing their investments in COVID-19 vaccine research. This is projected to add substantially to the market’s growth.
- North America holds the leading position.
- The Asia Pacific OTC deficiency market is projected to expand at a relatively high CAGR over the forecast period.
The global ornithine-transcarbamylase deficiency market is classified into:
- North America
- Asia Pacific
- Latin America
- Rest of the World
Companies Mentioned in the Report
- Ultragenyx Pharmaceutical
- Ucyclyd Pharma
- Horizon Therapeutics Plc
- OrphanPacific, Inc.
- Altis Endurance LLC
- Seqens Group
- Bausch Health Companies Inc.
- Unicyte AG
- Lucane Pharma SA
- Promethera Biosciences SA
Company Name: Report Ocean
Contact Person: Nishi Sharma
Email: Send Email
Address:Classic Tower, Rajnagar Extension
State: UP, 201017